Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics ...

Arrowhead said it has met both of these conditions in a July 28 release and now expects to receive the $100 million within 60 days. The company also said it plans on reaching the second enrollment ...

Arrowhead Pharmaceuticals ( NASDAQ: ARWR) Monday announced that it has earned a $100 million milestone payment from Sarepta Therapeutics ( NASDAQ: SRPT ).

When Pasadena-based Arrowhead Pharmaceuticals Inc. signed a huge licensing and collaboration deal with Cambridge, ...

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

Arrowhead Pharmaceuticals said it earned a $100 million milestone payment from Sarepta Therapeutics. The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets ...

Arrowhead Pharmaceuticals Inc. said Monday that it’s owed a $100 million milestone payment from Sarepta Therapeutics Inc. within the next two months, pressuring the beleaguered biotech company just ...

Sarepta Therapeutics (SRPT) shares dropped sharply on Monday following news that the FDA is investigating a patient death potentially connected to its gene therapy, Elevidys.

Sarepta Therapeutics shares jumped over 36% in premarket trading on Tuesday after the company said it had received US Food ...